Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mengyuan Zhu is active.

Publication


Featured researches published by Mengyuan Zhu.


CNS Neuroscience & Therapeutics | 2016

Amiloride Analogs as ASIC1a Inhibitors

Tian-Dong Leng; Hongfang Si; Jun Li; Tao Yang; Mengyuan Zhu; Binghe Wang; Roger P. Simon; Zhi-Gang Xiong

ASIC1a, the predominant acid‐sensing ion channels (ASICs), is implicated in neurological disorders including stroke, traumatic spinal cord injury, and ALS. Potent ASIC1a inhibitors should have promising therapeutic potential for ASIC1a‐related diseases.


Chemistry: A European Journal | 2017

Organic CO-prodrugs: Structure CO-release rate relationship Studies

Zhixiang Pan; Vayou Chittavong; Wei Li; Jun Zhang; Kaili Ji; Mengyuan Zhu; Xingyue Ji; Binghe Wang

Carbon monoxide (CO) is an endogenously produced gasotransmitter in mammals, and may have signaling roles in bacteria as well. It has many recognized therapeutic effects. A significant challenge in this field is the development of pharmaceutically acceptable forms of CO delivery with controllable and tunable release rates. Herein, the structure-release rate studies of the first class of organic CO prodrugs that release CO in aqueous solution at neutral pH is described.


European Journal of Medicinal Chemistry | 2017

Design, synthesis and antimicrobial activities of thiouracil derivatives containing triazolo-thiadiazole as SecA inhibitors

Penglei Cui; Xiaoliu Li; Mengyuan Zhu; Binghe Wang; Jing Liu; Hua Chen

A series of novel thiouracil derivatives containing a triazolo-thiadiazole moiety (7a-7l) have been synthesized by structural modifications on a lead SecA inhibitor, 2. All the compounds have been evaluated for their antibacterial activities against Bacillus amyloliquefaciens, Staphylococcus aureus, and Bacillus subtilis. Compounds 7d and 7g were also tested for their inhibitory activities against SecA ATPase due to their promising antimicrobial activities. The inhibitory activity of compound 7d was found to be higher than that of 2. Molecular docking work suggests that compound 7d might bind at a pocket close to the ATPase ATP-binding domain.


Bioorganic & Medicinal Chemistry Letters | 2015

A fluorescent bisboronic acid compound that selectively labels cells expressing oligosaccharide Lewis X.

Xingming Gao; Mengyuan Zhu; Haiying Fan; Wenqian Yang; Weijuan Ni; Vishnu Vardhan Reddy Karnati; Shouhai Gao; John L. Carson; Brent W. Weston; Binghe Wang

Two fluorescent diboronic acid compounds (6a and 6b) with a dipeptide linker were synthesized as potential sensors for cell surface saccharide Lewis X (Le(X)). Compound 6a with a dipeptide (H-Asp-Ala-) as the linker was found to selectively label CHOFUT4 cells, which express Le(x), at micromolar concentrations, while non-Le(x)-expressing control cells were not labeled.


Journal of Organic Chemistry | 2017

Click and Fluoresce: A Bioorthogonally Activated Smart Probe for Wash-Free Fluorescent Labeling of Biomolecules.

Xingyue Ji; Kaili Ji; Vayou Chittavong; Robert E. Aghoghovbia; Mengyuan Zhu; Binghe Wang

Bioorthogonally activated smart probes greatly facilitate the selective labeling of biomolecules in living system. Herein, we described a novel type of smart probes with tunable reaction rates, high fluorescence turn-on ratio, and easy access. The practicality of such probes was demonstrated by selective labeling of lipid and hCAII in Hela cells.


Oncotarget | 2017

Discovery and evaluation of triple inhibitors of VEGFR-2, TIE-2 and EphB4 as anti-angiogenic and anti-cancer agents

Lin Zhang; Yuanyuan Shan; Xingyue Ji; Mengyuan Zhu; Chuansheng Li; Ying Sun; Ru Si; Xiaoyan Pan; Jinfeng Wang; Weina Ma; Bingling Dai; Binghe Wang; Jie Zhang

Receptor tyrosine kinases (RTKs), especially VEGFR-2, TIE-2, and EphB4, play a crucial role in both angiogenesis and tumorigenesis. Moreover, complexity and heterogeneity of angiogenesis make it difficult to treat such pathological traits with single-target agents. Herein, we developed two classes of multi-target RTK inhibitors (RTKIs) based on the highly conserved ATP-binding pocket of VEGFR-2/TIE-2/EphB4, using previously reported BPS-7 as a lead compound. These multi-target RTKIs exhibited considerable potential as novel anti-angiogenic and anticancer agents. Among them, QDAU5 displayed the most promising potency and selectivity. It significantly suppressed viability of EA.hy926 and proliferation of several cancer cells. Further investigations indicated that QDAU5 showed high affinity to VEGFR-2 and reduced the phosphorylation of VEGFR-2. We identified QDAU5 as a potent multiple RTKs inhibitor exhibiting prominent anti-angiogenic and anticancer potency both in vitro and in vivo. Moreover, quinazolin-4(3H)-one has been identified as an excellent hinge binding moiety for multi-target inhibitors of angiogenic VEGFR-2, Tie-2, and EphB4.


Bioorganic & Medicinal Chemistry Letters | 2017

Design, synthesis and antibacterial activities of thiouracil derivatives containing acyl thiourea as SecA inhibitors

Penglei Cui; Xiaoliu Li; Mengyuan Zhu; Binghe Wang; Jing Liu; Hua Chen

A series of novel thiouracil derivatives containing an acyl thiourea moiety (7a-7x) have been synthesized by structural modification of a lead SecA inhibitor, 2. All the compounds have been evaluated for their antibacterial activities against Bacillus amyloliquefaciens, Staphylococcus aureus, and Bacillus subtilis. Compounds 7c, 7m, 7u, 7v exhibited promising activities against above bacteria. Such four compounds were further tested for their inhibitory activity against SecA ATPase, and the results showed that compounds 7c and 7u had higher inhibitory activities than that of compound 2. Molecular docking work suggests that compound 7u might bind at a pocket close to the ATPase ATP-binding domain.


Heterocyclic Communications | 2017

Boron-based small molecules in disease detection and treatment (2013–2016)

Suresh Thareja; Mengyuan Zhu; Xingyue Ji; Binghe Wang

Abstract Recent years have seen tremendous development in the design and synthesis of boron-based compounds as potential therapeutics and for detection applications. The present review highlights the most recent development of these boron-based small molecules, covering clinically used ixazomib, tavaborole, crisaborole and other molecules from 2013 to 2016.


European Journal of Medicinal Chemistry | 2016

Discovery of novel small molecule inhibitors of lysine methyltransferase G9a and their mechanism in leukemia cell lines.

Shukkoor Muhammed Kondengaden; Liu-fei Luo; Kenneth Huang; Mengyuan Zhu; Lanlan Zang; Eudoxie Bataba; Runling Wang; Cheng Luo; Binghe Wang; Keqin Kathy Li; Peng George Wang


Nature Chemistry | 2018

Enrichment-triggered prodrug activation demonstrated through mitochondria-targeted delivery of doxorubicin and carbon monoxide

Yueqin Zheng; Xingyue Ji; Bingchen Yu; Kaili Ji; David Gallo; Eva Csizmadia; Mengyuan Zhu; Manjusha Roy Choudhury; Ladie Kimberly De La Cruz; Vayou Chittavong; Zhixiang Pan; Zhengnan Yuan; Leo E. Otterbein; Binghe Wang

Collaboration


Dive into the Mengyuan Zhu's collaboration.

Top Co-Authors

Avatar

Binghe Wang

Georgia State University

View shared research outputs
Top Co-Authors

Avatar

Xingyue Ji

Georgia State University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kaili Ji

Georgia State University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jing Liu

Agricultural University of Hebei

View shared research outputs
Top Co-Authors

Avatar

Penglei Cui

Agricultural University of Hebei

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge